Despite policy uncertainty, regulatory flux, and shifting global dynamics, the pharmaceutical industry is on track to surpass $1.75 trillion in prescription drug sales by the end of the decade. In our annual World Preview report, we investigate emerging therapeutic trends, market disruptors, and the evolving role of China and AI in reshaping R&D and dealmaking.

From the meteoric rise of GLP-1s to the trend towards multi-indication blockbusters, this year’s World Preview highlights the resilience and adaptability of the biopharma sector. Whether you’re navigating patent cliffs, scouting licensing opportunities, or planning your next investment, this report is your essential guide to the future of pharma.

Key Highlights:

• GLP-1s dominate: Projected to account for nearly 9% of global drug sales by 2030
• China’s biotech boom: Chinese-origin assets will make up nearly 40% of global licensing deals in 2025
• Patent cliffs ahead: Over $300 billion in sales at risk by 2030